Patrick Wood, an analyst from Morgan Stanley, maintained the Sell rating on Staar Surgical (STAA – Research Report). The associated price target remains the same with $13.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Patrick Wood has given his Sell rating due to a combination of factors impacting Staar Surgical’s outlook. The company is navigating a challenging refractive market and macroeconomic uncertainties, which have led to the withdrawal of its 2025 guidance. This decision, while understandable, has raised concerns among investors, as it indicates potential short-term weaknesses, particularly in gross margins.
Additionally, while Staar Surgical has highlighted the potential of its proprietary collamer material and opportunities in ophthalmologic therapeutic settings, significant barriers such as financial and marketing challenges remain. Despite positive developments in the Chinese market and a new management team’s focus on return on investment, these factors contribute to a cautious outlook, prompting the Sell rating.
Wood covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Baxter International, and Edwards Lifesciences. According to TipRanks, Wood has an average return of -1.0% and a 50.00% success rate on recommended stocks.